Pith. sign in

REVIEW 4 major objections 4 minor 1 cited by

Leveraging Gene Expression Data and Explainable Machine Learning for Enhanced Early Detection of Type 2 Diabetes

T0 review · 4 major / 4 minor · reviewed 2026-08-12 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read This paper claims that an XGBoost model trained on single-cell islet gene expression distinguishes Type 2 diabetes from non-diabetic samples with 97% test accuracy, and that this outperforms earlier clinical and gene-expression models.

desk verdict The 97% XGBoost accuracy is almost certainly an artifact of donor leakage from cell-level random splitting, and the 'early detection' framing is unsupported; the paper is a routine ML benchmark with a load-bearing evaluation flaw. read the letter →

arxiv 2411.14471 v1 pith:7A2EJVT5 submitted 2024-11-18 q-bio.GN cs.AI

Aurora Lithe Roy , Md Kamrul Siam , Nuzhat Noor Islam Prova , Sumaiya Jahan , Abdullah Al Maruf This is my paper · ORCID
classification q-bio.GNcs.AI
keywords type2diabetesgeneexpressionXGBoostsingle-cellRNA-seqmachinelearningSHAPearlydetectionpancreaticislets
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

Using single-cell RNA sequencing data from human pancreatic islet cells, this paper tests whether machine learning can distinguish Type 2 diabetes from non-diabetic samples by gene expression alone. Across six classifiers, the XGBoost model reaches a reported 97% test accuracy, with high precision and recall, and the authors argue this supports a new route to early T2D detection. The result is presented as an improvement over prior models that mostly relied on clinical or demographic features.

What carries the argument

The load-bearing object is the XGBoost ensemble classifier with the hyperparameters listed in Table 1, applied to an 80/20 random split of single-cell expression profiles. The paper also uses SHAP values on a subset of test samples to rank gene contributions.

What would settle it

Train and test the same XGBoost pipeline with all cells from each organ donor kept together in either the training or test set, then compare the resulting accuracy with the reported 97%; a large drop would show the original figure was inflated by donor or batch leakage.

Watch

Extended reading notes

Core claim

The central claim is that the XGBoost classifier, trained on 28,089 gene expression features from 1,600 single islet cells (949 T2D, 651 non-diabetic), attains 97% test accuracy, a 97.91% precision, 96.90% recall, and a Matthews correlation coefficient of 94.28%. The paper attributes the strong performance to the boosting ensemble's ability to capture subtle expression differences and reports SHAP analysis showing, for example, HLA-A.3 as the most influential gene. It further claims this accuracy exceeds earlier gene-expression and clinical-data models.

Load-bearing premise

The paper assumes that the 1,600 single cells are independent biological replicates, so randomly splitting them into training and test sets gives a valid measure of how well the model would perform on new patients; this fails if cells from the same donor share expression patterns and appear in both splits.

Editorial extensions

If this is right

  • If the 97% accuracy generalizes beyond this dataset, gene expression profiling could complement blood-glucose screening for early Type 2 diabetes detection.
  • The genes flagged by SHAP, such as HLA-A.3, become candidate biomarkers that merit prospective validation in independent cohorts.
  • The reported superiority over prior models suggests boosting ensembles are well suited to high-dimensional expression data, motivating similar analyses on other islet datasets.
  • High accuracy despite a class imbalance (949 vs 651) hints that the classification signal is not driven solely by majority-class bias, assuming the split is valid.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • The random cell-level split likely leaks donor identity: cells from the same organ donor are correlated through donor-specific expression and batch effects, so the 97% figure may overstate generalization to new individuals.
  • A donor-stratified split (all cells of a donor kept together in either the training or test set) would directly test this; if accuracy drops substantially, the model is learning donor or batch signatures rather than a universal T2D signal.
  • The SHAP-identified features should be checked for overlap with known Type 2 diabetes GWAS loci; if the top genes are technical artifacts, the biological interpretation weakens.
  • The comparison with prior studies mixes different datasets, outcome definitions, and data types, so the claimed outperformance needs head-to-head evaluation on a shared benchmark.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 4 minor

Summary. The manuscript applies six machine-learning classifiers (DT, RF, LR, AdaBoost, GB, XGBoost) to single-cell RNA-seq data from GSE81608, consisting of 1,600 human pancreatic islet cells from T2D and non-diabetic organ donors, to classify T2D status. The authors report that XGBoost achieves 97% test accuracy, with supporting precision, recall, F1, Kappa, and MCC values, and they present SHAP analyses of the top model. They claim that this result outperforms previous studies and supports early detection of T2D from gene expression data.

Significance. If the central accuracy claim were valid, the paper would offer evidence that single-cell islet gene expression carries a large, generalizable T2D classification signal, which would be a meaningful contribution to computational diabetes research. The use of explainability (SHAP) is also a useful direction. However, the paper provides no donor-stratified evaluation, no external validation, no confidence intervals, and no reproducibility artifacts such as code or scripts. The reported evaluation protocol is vulnerable to donor and batch leakage, so the 97% accuracy cannot currently be interpreted as evidence of generalization to new individuals. The 'early detection' framing is also unsupported by the data, which come from already diagnosed T2D organ donors. These issues are load-bearing rather than cosmetic.

major comments (4)
  1. [Section 3.1 and Section 4.1, Table 2] The evaluation uses a single random 80/20 train_test_split at the level of individual cells. GSE81608 contains many cells per organ donor, and the paper does not report the number of donors or stratify the split by donor. Cells from the same donor can therefore appear in both the training and test sets, allowing XGBoost and other flexible models to memorize donor-specific or batch-specific expression patterns. The near-perfect training accuracy (100%) across most models and the sharp drop for RF, DT, and LR are consistent with this leakage. A donor-stratified cross-validation or at minimum a per-donor held-out evaluation is required before the 97% test accuracy can be claimed as a measure of generalization.
  2. [Abstract and Section 5] The paper repeatedly frames the contribution as 'early detection' of T2D, but the data are from organ donors with established T2D and non-diabetic controls in GSE81608. There is no prediabetic or early-stage cohort, and the analysis is a cross-sectional classification of already diagnosed individuals. Even a perfectly valid classifier trained on these data would not demonstrate early detection, so this framing overstates the clinical implications of the results.
  3. [Section 4.4, Table 5] The comparative claim that the proposed model 'outperformed previous studies' is not supported. Table 5 compares accuracy values across different datasets, different feature types (clinical, demographic, survey, administrative, genomic), and different experimental designs, with no matched evaluation protocol. For example, the comparison with [7] uses a different GEO dataset and a different model, and the comparison with [8] uses the Pima Indian clinical dataset. Accuracy differences across such heterogeneous settings do not establish superiority. The dataset identifier in Table 5 is also typoed as 'GSE8160' instead of 'GSE81608'.
  4. [Section 4.1 and Table 2] All results are reported from a single data split, with no confidence intervals, no repeated runs, and no hyperparameter tuning procedure described. The hyperparameters in Table 1 appear to be chosen on the same dataset, and there is no separate validation set or nested cross-validation. Consequently, the reported 97% accuracy, precision, recall, and MCC values have unknown variability, and the claim that XGBoost is reliably better than GB (97% vs. 97%) is not statistically supported.
minor comments (4)
  1. [Section 4.4] The SHAP analysis is restricted to the first 20 samples of the test set (X_test[0:20]); this is a very small and potentially nonrepresentative subset, and the paper should justify why this subset is sufficient for claiming model-level interpretability.
  2. [Table 2] Execution times are reported without specifying the hardware, software versions, or environment, which makes the runtime comparison non-reproducible.
  3. [Section 3.1] The paper states that the dataset is imbalanced (949 T2D vs. 651 non-diabetic samples) but does not report whether stratified splitting or class-weight handling was used; this should be clarified.
  4. [Section 1] The introduction and related work cite several studies, but the comparison in Section 4.4 uses a different numbering scheme in Table 5 (e.g., [6], [7], [8]) that is not clearly aligned with the reference list; the table should use the same citation keys as the text.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the paper reports an empirical classification accuracy rather than a derivation, and its accuracy claim does not reduce by construction to its inputs.

full rationale

The paper's central claim is an empirical performance measurement: XGBoost reaches 97% test accuracy on a random 80/20 split of GSE81608 single-cell samples. This is not a derivational claim in which an output equation is equivalent to an input by definition, and no fitted parameter is renamed as a prediction. The authors do not invoke any uniqueness theorem or self-citation chain to justify their model choice; the cited GREIN and GEO resources are data sources, not load-bearing self-citations. Hyperparameter choices in Table 1 are fixed settings rather than quantities fitted to the target outcome, and the test set is described as separate from training. The principal methodological threat, donor-level leakage due to cell-level random splitting, is a validity concern about whether the accuracy generalizes to new individuals, not a circularity whereby the prediction reduces to the training input by construction. The paper can therefore be assessed as essentially non-circular, with any weaknesses falling under correctness or experimental design rather than circular reasoning.

Assumptions & free parameters 2 free parameters · 3 assumptions · 0 invented entities

The central claim rests on the assumption that each single cell is an independent sample, that T2D donor status stands in for early disease, and that the normalized expression data need no batch correction. The model hyperparameters and the unreported split seed are hand-chosen inputs. No invented entities are introduced.

free parameters (2)
  • Random train/test split seed = not reported
    The exact split is not specified; the reported 97% accuracy depends on this choice, and no repeated splits are reported.
  • XGBoost hyperparameters = max_depth 6, learning_rate 0.1, subsample 0.8, colsample_bytree 0.8, gamma 0, lambda 1, alpha 0
    Chosen by hand in Table 1 without a reported hyperparameter search or nested cross-validation; performance could vary with different values.
assumptions (3)
  • domain assumption Single-cell samples are independent units, so a random cell-level split produces independent training and test sets.
    This is needed for the accuracy claim, but cells from the same organ donor are not independent; the paper does not stratify by donor in Section 3.1.
  • domain assumption T2D organ donor status is a valid proxy for early disease stage.
    The dataset contains diagnosed T2D donors, not prediabetic or early-stage patients; the conclusion about early detection requires this unsupported proxy.
  • domain assumption The GREIN-normalized gene-level expression values are comparable across samples without additional batch correction.
    The analysis uses downloaded normalized data from GREIN and does not report batch correction or detailed quality-control filtering in Section 3.1.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Leveraging Gene Expression Data and Explainable Machine Learning for Enhanced Early Detection of Type 2 Diabetes." pith.science (2026). https://pith.science/paper/7A2EJVT5

@misc{pith2026241114471,
  author       = {Pith},
  title        = {Pith review of: Leveraging Gene Expression Data and Explainable Machine Learning for Enhanced Early Detection of Type 2 Diabetes},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/7A2EJVT5}},
  note         = {Machine review of arXiv:2411.14471}
}
read the original abstract

Diabetes, particularly Type 2 diabetes (T2D), poses a substantial global health burden, compounded by its associated complications such as cardiovascular diseases, kidney failure, and vision impairment. Early detection of T2D is critical for improving healthcare outcomes and optimizing resource allocation. In this study, we address the gap in early T2D detection by leveraging machine learning (ML) techniques on gene expression data obtained from T2D patients. Our primary objective was to enhance the accuracy of early T2D detection through advanced ML methodologies and increase the model's trustworthiness using the explainable artificial intelligence (XAI) technique. Analyzing the biological mechanisms underlying T2D through gene expression datasets represents a novel research frontier, relatively less explored in previous studies. While numerous investigations have focused on utilizing clinical and demographic data for T2D prediction, the integration of molecular insights from gene expression datasets offers a unique and promising avenue for understanding the pathophysiology of the disease. By employing six ML classifiers on data sourced from NCBI's Gene Expression Omnibus (GEO), we observed promising performance across all models. Notably, the XGBoost classifier exhibited the highest accuracy, achieving 97%. Our study addresses a notable gap in early T2D detection methodologies, emphasizing the importance of leveraging gene expression data and advanced ML techniques.

Figures

Figures reproduced from arXiv: 2411.14471 by the authors.

Figure 1
Figure 1. General Architecture of XGBoost [PITH_FULL_IMAGE:figures/full_fig_p005_1.png] view at source ↗
Figure 2
Figure 2. Training and validation accuracy of XGBoost model [PITH_FULL_IMAGE:figures/full_fig_p006_2.png] view at source ↗
Figure 3
Figure 3. Training and validation loss of XGBoost model [PITH_FULL_IMAGE:figures/full_fig_p006_3.png] view at source ↗
Figures from the paper (1 more)
Figure 5
Figure 5. Figure 5: SHAP features impact on the model’s prediction [PITH_FULL_IMAGE:figures/full_fig_p007_5.png]

Discussion (0). Continue with ORCID to comment.

Forward citations

Cited by 1 Pith paper

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score. Full citation record

  1. Do We Need Pre-Processing for Deep Learning Based Ultrasound Shear Wave Elastography?

    eess.IV 2025-08 unverdicted novelty 5.0 of 10

    A 3D convolutional network can estimate shear wave velocity from raw ultrasound radiofrequency data without conventional preprocessing, though preprocessing slightly improves metrics.

Reference graph

Works this paper leans on

24 extracted references · 17 canonical work pages · cited by 1 Pith paper

  1. [7]

    Torres-Mata, Sara Cazorla-Rivero, Cristina Fernández-Santana, Estrella Gómez-Bentolila, Bernardino Clavo, and Francisco Rodríguez-Esparragón

    Jesús María González-Martín, Laura B. Torres-Mata, Sara Cazorla-Rivero, Cristina Fernández-Santana, Estrella Gómez-Bentolila, Bernardino Clavo, and Francisco Rodríguez-Esparragón. 2023. An Artificial Intelligence Prediction Model of In- sulin Sensitivity, Insulin Resistance, and Diabetes Using Genes Obtained through Differential Expression. Genes 14, 12 (...

    work page 2023

  2. [8]

    Shahriare Satu, Md

    Koushik Chandra Howlader, Md. Shahriare Satu, Md. Abdul Awal, Md. Rabiul Islam, Sheikh Mohammed Shariful Islam, Julian M. W. Quinn, and Mohammad Ali Moni. 2022. Machine learning models for classification and identification of significant attributes to detect type 2 diabetes. Health Information Science and Systems 10, 1 (Feb. 2022). https://doi.org/10.1007...

    work page doi:10.1007/s13755-021-00168-2 2022

  3. [1]

    Antonio Agliata, Deborah Giordano, Francesco Bardozzo, Salvatore Bottiglieri, Angelo Facchiano, and Roberto Tagliaferri. 2023. Machine Learning as a Support for the Diagnosis of Type 2 Diabetes. International Journal of Molecular Sciences 24, 7 (April 2023), 6775. https://doi.org/10.3390/ijms24076775

    work page doi:10.3390/ijms24076775 2023

  4. [2]

    Gabriel Aguilera-Venegas, Amador López-Molina, Gemma Rojo-Martínez, and José Luis Galán-García. 2023. Comparing and tuning machine learning algorithms to predict type 2 diabetes mellitus. J. Comput. Appl. Math. 427 (Aug. 2023), 115115. https://doi.org/10.1016/j.cam.2023.115115

    work page arXiv 2023

  5. [3]

    Usama Ahmed, Ghassan F Issa, Muhammad Adnan Khan, Shabib Aftab, Muham- mad Farhan Khan, Raed AT Said, Taher M Ghazal, and Munir Ahmad. 2022. Prediction of Diabetes Empowered With Fused Machine Learning. IEEE Access 10 (2022), 8529–8538. https://doi.org/10.1109/access.2022.3142097

    arXiv 2022

  6. [4]

    Barrett, D

    T. Barrett, D. B. Troup, S. E. Wilhite, P. Ledoux, C. Evangelista, I. F. Kim, M. Tomashevsky, K. A. Marshall, K. H. Phillippy, P. M. Sherman, R. N. Muertter, M. Holko, O. Ayanbule, A. Yefanov, and A. Soboleva. 2010. NCBI GEO: archive for functional genomics data sets–10 years on. Nucleic Acids Research 39, Database (Nov. 2010), D1005–D1010. https://doi.or...

    work page doi:10.1093/nar/gkq1184 2010

  7. [5]

    Nikos Fazakis, Otilia Kocsis, Elias Dritsas, Sotiris Alexiou, Nikos Fakotakis, and Konstantinos Moustakas. 2021. Machine Learning Tools for Long-Term Type 2 Diabetes Risk Prediction. IEEE Access 9 (2021), 103737–103757. https://doi.org/ 10.1109/access.2021.3098691

    arXiv 2021

  8. [6]

    Shahid Mohammad Ganie, Majid Bashir Malik, and Tasleem Arif. 2022. Perfor- mance analysis and prediction of type 2 diabetes mellitus based on lifestyle data using machine learning approaches. Journal of Diabetes & Metabolic Disor- ders 21, 1 (March 2022), 339–352. https://doi.org/10.1007/s40200-022-00981-w

    work page doi:10.1007/s40200-022-00981-w 2022

Show all 24 references
  1. [9]

    Orlando Iparraguirre-Villanueva, Karina Espinola-Linares, Rosalynn Ornella Flo- res Castañeda, and Michael Cabanillas-Carbonell. 2023. Application of machine learning models for early detection and accurate classification of type 2 diabetes. Diagnostics (Basel) 13, 14 (July 2023)

    2023

  2. [10]

    Joshi and Chandra K

    Ram D. Joshi and Chandra K. Dhakal. 2021. Predicting Type 2 Diabetes Using Logistic Regression and Machine Learning Approaches. International Journal of Environmental Research and Public Health 18, 14 (July 2021), 7346. https: //doi.org/10.3390/ijerph18147346

    2021 doi

  3. [11]

    Hanieh Karmand, Aref Andishgar, Reza Tabrizi, Alireza Sadeghi, Babak Pezeshki, Mahdi Ravankhah, Erfan Taherifard, and Fariba Ahmadizar. 2024. Machine- learning algorithms in screening for type 2 diabetes mellitus: Data from Fasa Adults Cohort Study. Endocrinology, Diabetes &am...

    2024 doi

  4. [12]

    Fayroza Alaa Khaleel and Abbas M Al-Bakry. 2023. Diagnosis of diabetes using machine learning algorithms. Materials Today: Proceedings 80 (2023), 3200–3203. https://doi.org/10.1016/j.matpr.2021.07.196

    2023 doi

  5. [13]

    Raja Krishnamoorthi, Shubham Joshi, Hatim Z Almarzouki, Piyush Kumar Shukla, Ali Rizwan, C Kalpana, Basant Tiwari, et al. 2022. A Novel Diabetes Healthcare Disease Prediction Framework Using Machine Learning Techniques. Journal of Healthcare Engineering 2022 (Jan. 2022), 1–10....

    2022 doi

  6. [14]

    Haohui Lu, Shahadat Uddin, Farshid Hajati, Mohammad Ali Moni, and Matloob Khushi. 2021. A patient network-based machine learning model for disease prediction: The case of type 2 diabetes mellitus. Applied Intelligence 52, 3 (June 2021), 2411–2422. https://doi.org/10.1007/s1048...

    2021 doi

  7. [15]

    Naim Al Mahi, Mehdi Fazel Najafabadi, Marcin Pilarczyk, Michal Kouril, and Mario Medvedovic. 2019. GREIN: An interactive web platform for re-analyzing GEO RNA-seq data. Sci. Rep. 9, 1 (May 2019), 7580

    2019

  8. [16]

    Karuna Middha and Apeksha Mittal. 2023. An effective feature selection method for type 2 diabetes mellitus detection using gene expression data. Intelligent Decision Technologies 17, 3 (July 2023), 595–606. https://doi.org/10.3233/idt- 220077

    2023 doi

  9. [17]

    Nurjahan Nipa, Mahmudul Hasan Riyad, Shahriare Satu, Walliullah, Koushik Chandra Howlader, and Mohammad Ali Moni. 2024. Clinically adaptable machine learning model to identify early appreciable features of diabetes. Intelli- gent Medicine 4, 1 (Feb. 2024), 22–32. https://doi.o...

    2024 doi

  10. [18]

    Amos Otieno Olwendo, George Ochieng, and Kenneth Rucha. 2023. Comparison of machine learning methods for the prediction of type 2 diabetes in primary care setting using EHR data. Journal of Agriculture, Science and Technology 23, 1 (Oct. 2023), 24–36. https://doi.org/10.4314/j...

    2023 doi

  11. [19]

    Xiaoting Pei, Di Qi, Jiangman Liu, Hongli Si, Shenzhen Huang, Sen Zou, Dingli Lu, and Zhijie Li. 2023. Screening marker genes of type 2 diabetes mellitus in mouse lacrimal gland by LASSO regression. Scientific Reports 13, 1 (April 2023). https://doi.org/10.1038/s41598-023-34072-4

    2023 doi

  12. [20]

    Quang, Michael R

    Vivek Rai, Daniel X. Quang, Michael R. Erdos, Darren A. Cusanovich, Riza M. Daza, Narisu Narisu, Luli S. Zou, John P. Didion, Yuanfang Guan, Jay Shendure, Stephen C.J. Parker, and Francis S. Collins. 2020. Single-cell ATAC-Seq in human pancreatic islets and deep learning upsca...

    2020 doi

  13. [21]

    Aditya Saxena, Nitish Mathur, Pooja Pathak, Pradeep Tiwari, and Sandeep Kumar Mathur. 2023. Machine Learning Model Based on Insulin Resistance Metagenes Underpins Genetic Basis of Type 2 Diabetes. Biomolecules 13, 3 (Feb. 2023), 432. https://doi.org/10.3390/biom13030432

    2023 doi

  14. [22]

    Nobuhiro Shojima and Toshimasa Yamauchi. 2023. Progress in genetics of type 2 diabetes and diabetic complications. Journal of Diabetes Investigation 14, 4 (Jan. 2023), 503–515. https://doi.org/10.1111/jdi.13970

    2023 doi

  15. [23]

    Parvathaneni Naga Srinivasu, Jana Shafi, T Balamurali Krishna, Canavoy Narahari Sujatha, S Phani Praveen, and Muhammad Fazal Ijaz. 2022. Using Recurrent Neural Networks for Predicting Type-2 Diabetes from Genomic and Tabular Data. Diagnostics 12, 12 (Dec. 2022), 3067. https://...

    2022 doi

  16. [24]

    Murphy, George D

    Yurong Xin, Jinrang Kim, Haruka Okamoto, Min Ni, Yi Wei, Christina Adler, Andrew J. Murphy, George D. Yancopoulos, Calvin Lin, and Jesper Gromada. 2016. RNA Sequencing of Single Human Islet Cells Reveals Type 2 Diabetes Genes.Cell Metabolism 24, 4 (Oct. 2016), 608–615. https:/...

    2016 doi

Pith tools

Reviewed August 12, 2026 · model on record in the stance chip above.